Business Wire

MAXON

10.4.2024 15:32:31 CEST | Business Wire | Press release

Share
Maxon One Spring 2024 Release Packs Particle Power, Toon Shading, and More

Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists, and creators of all types, today announced a game-changing update to Maxon One.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409558753/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Maxon One Spring 2024 release showcases groundbreaking updates to Cinema 4D, Redshift, Red Giant and more to enable users to bring stories to life with unparalleled creative freedom. Artist credit: Something's Awry

Motion designers, broadcasters, VFX artists, and more rely on Maxon One to promote products, frame shows, and realize clients’ visions. And, just in time for NAB, this spring release is packed with new creativity-boosting upgrades and tools, including Cinema 4D Particles, NPR rendering in Redshift, and Red Giant Geo.

Feature Highlights Include:

Cinema 4D 
Cinema 4D 2024.4 empowers 3D VFX artists and motion designers to create complex scenes with ease.

  • Design particle simulations intuitively with new Cinema 4D Particles! Integration with C4D’s Unified Simulation systems allows artists to control emission patterns, modify behaviors precisely, and orchestrate interactions with Maxon’s collection of simulation types, including Pyro, Cloth, soft bodies, and rigid bodies. Render particles scenes with Redshift, or cache and export them via Alembic. New Cinema 4D Particles presets are available in the Asset Browser, giving artists creative options for starting any project.

Redshift 
Redshift 3.6.0 features non-photorealistic rendering (NPR), more flexible Standard Volumes, support for AMD graphics, alpha mask support for Redshift area lights and more.

  • Render NPR line and toon looks in Redshift with new non-photoreal-render options, including a Contour node, a Toon Material node for cel shading, and a Tonemap Pattern shader for half-tone shading and other screen-space, grid-based shading styles.

Red Giant 
Red Giant 2024.2 features Red Giant Geo, a new tool that lets users texture, light, and clone 3D objects in After Effects. Rendering performance in Trapcode Particular has been improved significantly and there are new custom blur maps for Bokeh, as well as improvements to Looks’ UI.

Capsules 
Maxon One subscribers enjoy access to the expansive Maxon Capsules library, which includes a wide variety of assets to help kickstart any project. In addition to the library of Adobe Substance 3D materials Maxon released in partnership with Adobe recently, this release includes many great new additions such as Ivy Generator, Partition Modifier and Wood Floors Vol. 01.

Cineware 
Updates to Cineware for Unreal make it easier than ever to transfer materials between Cinema 4D to Unreal. Use Direct Link, and there’s no need to save files to disk when transferring. Note: Only works with Unreal Engine 5.0 and beyond and requires Cinema 4D 2023.0 or later versions.

More details at maxon.net. Assets are available to download here.

About Maxon 
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409558753/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye